Elevar Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Lirafugratinib as Second-line Cholangiocarcinoma Treatment
FDA set a Sept. 27 PDUFA date for approval decision Lirafugratinib achieved a 46.5% ORR, in CCA patients with FGFR2 fusion and rearrangement Fort Lee, N.J., March 30 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to
